Sequence information
Variant position: 394 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 576 The length of the canonical sequence.
Location on the sequence:
EAFLGCPAIHPRCRWGAAPY
R GRPKLLQLPLGFLYVHHTYV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human EAFLGCPAIHPRCRWGAAPYR GRPKLLQLPLGFLYVHHTYV
Mouse EAFLGCPAIHPRCRWGAAPYR GHPTPLRLPLGFLYVHHTYV
Pig EAFLGCPAIHPRCRWGAAPYR GSPKPLKLPLGFLYIHHTYV
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
22 – 576
N-acetylmuramoyl-L-alanine amidase
Metal binding
410 – 410
Zinc; via pros nitrogen
Mutagenesis
411 – 411
H -> A. No effect on amidase activity.
Literature citations
Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.
Yamada S.; Ohira M.; Horie H.; Ando K.; Takayasu H.; Suzuki Y.; Sugano S.; Hirata T.; Goto T.; Matsunaga T.; Hiyama E.; Hayashi Y.; Ando H.; Suita S.; Kaneko M.; Sasaki F.; Hashizume K.; Ohnuma N.; Nakagawara A.;
Oncogene 23:5901-5911(2004)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT GLN-394;
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.
Clark H.F.; Gurney A.L.; Abaya E.; Baker K.; Baldwin D.T.; Brush J.; Chen J.; Chow B.; Chui C.; Crowley C.; Currell B.; Deuel B.; Dowd P.; Eaton D.; Foster J.S.; Grimaldi C.; Gu Q.; Hass P.E.; Heldens S.; Huang A.; Kim H.S.; Klimowski L.; Jin Y.; Johnson S.; Lee J.; Lewis L.; Liao D.; Mark M.R.; Robbie E.; Sanchez C.; Schoenfeld J.; Seshagiri S.; Simmons L.; Singh J.; Smith V.; Stinson J.; Vagts A.; Vandlen R.L.; Watanabe C.; Wieand D.; Woods K.; Xie M.-H.; Yansura D.G.; Yi S.; Yu G.; Yuan J.; Zhang M.; Zhang Z.; Goddard A.D.; Wood W.I.; Godowski P.J.; Gray A.M.;
Genome Res. 13:2265-2270(2003)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANTS ALA-46; GLN-99; LYS-270 AND GLN-394;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.